ES101

DRUG2 trials

Sponsors

Elpiscience Biopharma, Ltd.

Conditions

Malignant TumorNeoplasmsNon-small Cell Lung CancerSmall Cell Lung CancerSolid TumorsThoracic Tumors

Phase 1

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors

TerminatedNCT04009460

Elpiscience Biopharma, Ltd.Malignant Tumor, Neoplasms, Solid Tumors

Start: 2019-06-28End: 2022-04-22Updated: 2022-04-29

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors

WithdrawnNCT04841538

Elpiscience Biopharma, Ltd.Non-small Cell Lung Cancer, Small Cell Lung Cancer, Thoracic Tumors

Start: 2021-07-31End: 2024-05-31Updated: 2022-04-29